CERO.OOTC
- CERo Therapeutics Holdings, Inc.
報價延遲最少15分鐘:2025/12/14 05:36 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.04/-4.84
|
|
企業價值
1.90M
|
| 資產負債 |
|
每股賬面淨值
-5.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||
|
||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables itto integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. |
